ONO Takahiro

写真a

Affiliation

Graduate School of Medicine  Doctorial Course in Medicine  Organ Function-Oriented Medicine  Department of Neurosurgery

Graduating School 【 display / non-display

  •  
    -
    2009.03

    Akita University   Faculty of Medicine   Graduated

Graduate School 【 display / non-display

  •  
    -
    2015.03

    Akita University  Graduate School, Division of Medicine  Doctor's Course  Completed

Studying abroad experiences 【 display / non-display

  • 2015.11
    -
    2017.06

    Germany   Guest Researcher, Department of Neuropathology, Institute of Pathology, University Heidelberg

Campus Career 【 display / non-display

  • 2017.07
    -
    Now

    Akita University   Graduate School of Medicine   Doctorial Course in Medicine   Organ Function-Oriented Medicine   Assistant Professor  

 

Research Career 【 display / non-display

  • Refinement of IDH-mutated glioma classification and grading

    International Joint Research Projects  

    Periods of research:

    2015.11
    -
    2017.10

    Classification of research form:International Collaboration

  • Diagnostic significance of amino acid tracers for evaluation of temozolomide therapy with interferon-beta and bevacizumab in temozolomide-resistant malignant glioma

    Grant-in-Aid for Scientific Research  

    Periods of research:

    2011.04
    -
    2015.03

    Classification of research form:Collaboration within Japan

Published Papers 【 display / non-display

  • Adult cerebellar glioblastoma categorized into a pediatric methylation class with a unique radiological and histological appearance: illustrative case

    Takahiro Ono, Felix Hinz, Shogo Tanaka, Masataka Takahashi, Hiroshi Nanjo, Andreas von Deimling, Hiroaki Shimizu

    Journal of Neurosurgery: Case Lessons ( Journal of Neurosurgery Publishing Group (JNSPG) )  3 ( 14 )   2022.04  [Refereed]

    BACKGROUND

    Recent studies report that cerebellar glioblastoma (GBM) is categorized into the RTK1 methylation class. GBM pediatric RTK (pedRTK) subtypes are distinct from those of adult GBM. We present a unique adult case of cerebellar GBM classified into the pedRTK subtype.

    OBSERVATIONS

    Magnetic resonance imaging revealed a homogeneous enhancing lesion in the right cerebellum in a 56-year-old woman presenting with ataxia and dizziness. Arterial spin labeling and angiographic findings and the intraoperative orange-colored tumor appearance were reminiscent of hemangioblastoma. She showed an atypical presentation in terms of high glucose metabolism. The histological diagnosis was high-grade glioma with differentiation similar to central nervous system neuroblastoma. The methylation class was GBM pedRTK1. Consistent with this classification, immunoexpression was positive for SOX10 and negative for ANKRD55. She underwent craniospinal radiotherapy (23.4 Gy) with a boost to the tumor bed (total 55.8 Gy). Twelve courses of temozolomide therapy were administered. There was no recurrence 18 months after surgery.

    LESSONS

    Radiological and intraoperative findings, such as hemangioblastoma and high glucose metabolism, were notable characteristics in the present case. Both glial and neuronal differentiation and SOX10 immunoexpression were presenting pathological features. Similar cerebellar GBMs might form a previously unestablished subtype. Establishing effective molecular diagnoses is important.

    DOI

  • Oligosarcomas, IDH-mutant are distinct and aggressive

    Suwala A.K.

    Acta Neuropathologica ( Acta Neuropathologica )  143 ( 2 ) 263 - 281   2022.02  [Refereed]

    Oligodendrogliomas are defined at the molecular level by the presence of an IDH mutation and codeletion of chromosomal arms 1p and 19q. In the past, case reports and small studies described gliomas with sarcomatous features arising from oligodendrogliomas, so called oligosarcomas. Here, we report a series of 24 IDH-mutant oligosarcomas from 23 patients forming a distinct methylation class. The tumors were recurrences from prior oligodendrogliomas or developed de novo. Precursor tumors of 12 oligosarcomas were histologically and molecularly indistinguishable from conventional oligodendrogliomas. Oligosarcoma tumor cells were embedded in a dense network of reticulin fibers, frequently showing p53 accumulation, positivity for SMA and CALD1, loss of OLIG2 and gain of H3K27 trimethylation (H3K27me3) as compared to primary lesions. In 5 oligosarcomas no 1p/19q codeletion was detectable, although it was present in the primary lesions. Copy number neutral LOH was determined as underlying mechanism. Oligosarcomas harbored an increased chromosomal copy number variation load with frequent CDKN2A/B deletions. Proteomic profiling demonstrated oligosarcomas to be highly distinct from conventional CNS WHO grade 3 oligodendrogliomas with consistent evidence for a smooth muscle differentiation. Expression of several tumor suppressors was reduced with NF1 being lost frequently. In contrast, oncogenic YAP1 was aberrantly overexpressed in oligosarcomas. Panel sequencing revealed mutations in NF1 and TP53 along with IDH1/2 and TERT promoter mutations. Survival of patients was significantly poorer for oligosarcomas as first recurrence than for grade 3 oligodendrogliomas as first recurrence. These results establish oligosarcomas as a distinct group of IDH-mutant gliomas differing from conventional oligodendrogliomas on the histologic, epigenetic, proteomic, molecular and clinical level. The diagnosis can be based on the combined presence of (a) sarcomatous histology, (b) IDH-mutation and (c) TERT promoter mutation and/or 1p/19q codeletion, or, in unresolved cases, on its characteristic DNA methylation profile.

    DOI Repository PubMed

  • Clinical, histopathological, and molecular features of IDH-wildtype indolent diffuse glioma: comparison with typical glioblastoma

    Suzuki H.

    Journal of Neuro-Oncology ( Journal of Neuro-Oncology )    2022  [Refereed]

    PURPOSE: IDH-wildtype (IDHwt) diffuse gliomas are treated as glioblastoma, however, some of these may show less aggressive clinical courses. The authors investigated the clinical, histopathological, and molecular characteristics of such IDHwt indolent diffuse gliomas (iDGwt), which have not been well documented in the literature. METHODS: Adult patients with IDHwt gliomas admitted between 2011 and 2020 were surveyed. In this particular study, the clinical indolence was defined mainly as having a small enhancing lesion and a stable period for more than 1 month before surgery. The current WHO diagnostic criteria were adapted for the diagnoses. Gene mutations and copy number changes in 43 representative glioma-associated genes, MGMT promoter methylation status, and survival data were compared with those of The Cancer Genome Atlas reference cohort. RESULTS: Nine out of 180 surveyed cases (5.0%) fulfilled the present criteria of the iDGwt. Considering the representative regulatory pathways, 8 (88.9%), 4 (44.4%), and 1 (11.1%) case had genetic alterations in the PI3K/MAPK, TP53, and RB pathways, respectively. The frequency of the RB pathway alteration was significantly lower than that in the reference cohort (281 of 362 cases: 77.6%). Two cases (22.2%) showing EGFR amplification met the diagnostic criteria for glioblastoma, and the frequency was significantly lower than that in the reference cohort (412 of 426 cases: 96.7%). The overall survival (median: 37.5 months) in the present series was significantly longer than that in the reference cohort (n = 426, median: 13.9 months). CONCLUSIONS: iDGwt lacked the molecular features of glioblastoma except for the PI3K/MAPK pathway alteration.

    DOI PubMed

  • The Real-World status and risk factors for a poor prognosis in elderly patients with primary central nervous system malignant lymphomas: a multicenter, retrospective cohort study of the Tohoku Brain Tumor Study Group.

    Kenichiro Asano, Yoji Yamashita, Takahiro Ono, Manabu Natsumeda, Takaaki Beppu, Kenichiro Matsuda, Masahiro Ichikawa, Masayuki Kanamori, Masashi Matsuzaka, Akira Kurose, Kiyoshi Saito, Yukihiko Sonoda, Kuniaki Ogasawara, Yukihiko Fujii, Hiroaki Shimizu, Hiroki Ohkuma, Chifumi Kitanaka, Takamasa Kayama, Teiji Tominaga

    International journal of clinical oncology     2021.10  [Refereed]

    BACKGROUND: Elderly patients with primary central nervous system malignant lymphoma (EL-PCNSL) may not be given sufficient treatment due to their poor pre-treatment Karnofsky Performance Status (KPS) and comorbidities. Therefore, a retrospective, cohort study was performed to evaluate risk factors associated with a poor prognosis of EL-PCNSL in the Tohoku Brain Tumor Study Group. METHODS: Patients aged ≥ 71 years with PCNSL were enrolled from eight centers. Univariate analysis was performed with the log-rank test. A Cox proportional hazards model was used for multivariate analysis. RESULTS: Three of the total 142 cases received best supportive care (BSC). Treatment was given to 30 cases without a pathological diagnosis, 3 cases with cerebrospinal fluid (CSF) cytology, and 100 cases with a pathological diagnosis. After confirmation of no differences in progression-free survival (PFS) and overall survival (OS) between the group treated without pathology and the groups diagnosed by pathology or CSF cytology and between median age ≥ 76 years and < 76 years, a total of 133 patients were studied. The median pre-treatment KPS was 50%. Median PFS and median OS were 16 and 24 months, respectively. Risk factors associated with poor prognosis on Cox proportional hazards model analysis were pre-treatment cardiovascular disease and central nervous system disease comorbidities, post-treatment pneumonia and other infections, and the absence of radiotherapy or chemotherapy. CONCLUSIONS: Pre-treatment comorbidities and post-treatment complications would affect the prognosis. Radiation and chemotherapy were found to be effective, but no conclusions could be drawn regarding the appropriate content of chemotherapy and whether additional radiotherapy should be used.

    DOI PubMed

display all >>

Review Papers 【 display / non-display

  • Automation of novel rapid-immunohistochemistry (R-IHC)

    南條博, 廣嶋優子, 今井一博, 寺田かおり, 小野隆裕, 中村竜太, 大久保義真, 赤上陽一, 南谷佳弘

    日本病理学会会誌   110 ( 1 )   2021

    Unselected

    J-GLOBAL

  • The REAL-WORLD of Elderly PCNSL Therapy in Tohoku and Niigata Area According to Retrospective Analysis: A Collaborative Investigation of the Tohoku Brain Tumor Study Group

    浅野研一郎, 山下洋二, 小野隆裕, 棗田学, 別府高明, 松田憲一朗, 市川優寛, 金森政之, 松坂方士, 黒瀬顕, 齋藤清, 園田順彦, 小笠原邦昭, 藤井幸彦, 清水宏明, 大熊洋揮, 北中千史, 嘉山孝正, 冨永悌二

    日本脳腫瘍学会プログラム・抄録集   38th   2020

    Unselected

    J-GLOBAL

  • Intracerebral hemorrhage: the role of surgery

    鈴木隼士, 鈴木隼士, 小野隆裕, 山口卓, 西野克寛, 清水宏明

    脳卒中   41 ( 1 )   2019

    Unselected

    J-GLOBAL